{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:38:29Z","timestamp":1791639509206,"version":"4.3.4"},"reference-count":29,"publisher":"The Endocrine Society","issue":"4","license":[{"start":{"date-parts":[[2020,2,5]],"date-time":"2020-02-05T00:00:00Z","timestamp":1580860800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Growth hormone (GH) replacement requires daily GH injections, which is burdensome for some adult patients with GH deficiency (AGHD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To demonstrate efficacy and safety of somapacitan, a once-weekly reversible albumin-binding GH derivative, versus placebo in AGHD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Randomized, parallel-group, placebo-controlled (double-blind) and active-controlled (open-label) phase 3 trial, REAL 1 (NCT02229851).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Clinics in 17 countries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients<\/jats:title>\n                    <jats:p>Treatment-na\u00efve patients with AGHD (n = 301 main study period, 272 extension period); 257 patients completed the trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>Patients were randomized 2:2:1 to once-weekly somapacitan, daily GH, or once-weekly placebo for 34 weeks (main period). During the 52-week extension period, patients continued treatment with somapacitan or daily GH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main outcome measures<\/jats:title>\n                    <jats:p>Body composition measured using dual-energy x-ray absorptiometry (DXA). The primary endpoint was change in truncal fat percentage to week 34. Insulin-like growth factor 1 (IGF-I) standard deviation score (SDS) values were used to dose titrate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At 34 weeks, somapacitan significantly reduced truncal fat percentage (estimated difference: \u22121.53% [\u22122.68; \u22120.38]; P = 0.0090), demonstrating superiority compared with placebo, and it improved other body composition parameters (including visceral fat and lean body mass) and IGF-I SDS. At 86 weeks, improvements were maintained with both somapacitan and daily GH. Somapacitan was well tolerated, with similar adverse events (including injection-site reactions) compared with daily GH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In AGHD patients, somapacitan administered once weekly demonstrated superiority over placebo, and the overall treatment effects and safety of somapacitan were in accordance with known effects and safety of GH replacement for up to 86 weeks of treatment. Somapacitan may provide an effective alternative to daily GH in AGHD. A short visual summary of our work is available (1).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgaa049","type":"journal-article","created":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T21:34:18Z","timestamp":1581543258000},"page":"e1358-e1376","source":"Crossref","is-referenced-by-count":83,"title":["Once-weekly Somapacitan is Effective and Well Tolerated in Adults with GH Deficiency: A Randomized Phase 3 Trial"],"prefix":"10.1210","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3484-8440","authenticated-orcid":false,"given":"Gudmundur","family":"Johannsson","sequence":"first","affiliation":[{"name":"Sahlgrenska University Hospital, G\u00f6teborg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murray B","family":"Gordon","sequence":"additional","affiliation":[{"name":"Allegheny General Hospital, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2210-0366","authenticated-orcid":false,"given":"Michael","family":"H\u00f8jby Rasmussen","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S, S\u00f8borg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida Holme","family":"H\u00e5konsson","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S, S\u00f8borg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfram","family":"Karges","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Diabetes, RWTH Aachen University, Aachen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Sv\u00e6rke","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S, S\u00f8borg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeyuki","family":"Tahara","sequence":"additional","affiliation":[{"name":"Nippon Medical School, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Takano","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes and Metabolism, Kitasato University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverly M K","family":"Biller","sequence":"additional","affiliation":[{"name":"Neuroendocrine Unit, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2020,2,5]]},"reference":[{"key":"2021122209563806700_CIT0001","article-title":"Animated summary.","author":"Johannsson"},{"issue":"1","key":"2021122209563806700_CIT0002","doi-asserted-by":"crossref","first-page":"R47","DOI":"10.1530\/EJE-18-0306","article-title":"THERAPY OF ENDOCRINE DISEASE: Growth hormone replacement therapy in adults: 30 years of personal clinical experience","volume":"179","author":"J\u00f8rgensen","year":"2018","journal-title":"Eur J Endocrinol."},{"issue":"26","key":"2021122209563806700_CIT0003","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1056\/NEJMra1817346","article-title":"Pathogenesis and diagnosis of growth hormone deficiency in adults","volume":"380","author":"Melmed","year":"2019","journal-title":"N Engl J Med."},{"issue":"1","key":"2021122209563806700_CIT0004","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1530\/EJE-07-0013","article-title":"Mortality and GH deficiency: a nationwide study","volume":"157","author":"Stochholm","year":"2007","journal-title":"Eur J Endocrinol."},{"issue":"11","key":"2021122209563806700_CIT0005","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1210\/jc.2016-2118","article-title":"Hormonal replacement in hypopituitarism in adults: an endocrine society clinical practice guideline","volume":"101","author":"Fleseriu","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"issue":"6","key":"2021122209563806700_CIT0006","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1530\/EJE-07-0631","article-title":"Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia","volume":"157","author":"Ho","year":"2007","journal-title":"Eur J Endocrinol."},{"issue":"11","key":"2021122209563806700_CIT0007","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.4158\/GL-2019-0405","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of growth hormone deficiency in adults and patients transitioning from pediatric to adult care","volume":"25","author":"Yuen","year":"2019","journal-title":"Endocr Pract."},{"issue":"1","key":"2021122209563806700_CIT0008","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1179\/acb.2010.002","article-title":"Treatment of adult growth hormone deficiency: who, why and how? A review","volume":"65","author":"Alexopoulou","year":"2010","journal-title":"Acta Clin Belg."},{"issue":"12","key":"2021122209563806700_CIT0009","doi-asserted-by":"crossref","first-page":"6431","DOI":"10.1210\/jc.2005-0928","article-title":"Efficacy of a long-acting growth hormone (GH) preparation in patients with adult GH deficiency","volume":"90","author":"Hoffman","year":"2005","journal-title":"J Clin Endocrinol Metab."},{"issue":"6","key":"2021122209563806700_CIT0010","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1210\/jc.2010-2819","article-title":"Effects of once-weekly sustained-release growth hormone: a double-blind, placebo-controlled study in adult growth hormone deficiency","volume":"96","author":"Biller","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2021122209563806700_CIT0011","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1021\/js950412j","article-title":"Albumin binding and time action of acylated insulins in various species","volume":"85","author":"Kurtzhals","year":"1996","journal-title":"J Pharm Sci."},{"issue":"9","key":"2021122209563806700_CIT0012","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1021\/jm9909645","article-title":"Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration","volume":"43","author":"Knudsen","year":"2000","journal-title":"J Med Chem."},{"issue":"18","key":"2021122209563806700_CIT0013","doi-asserted-by":"crossref","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","article-title":"Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide","volume":"58","author":"Lau","year":"2015","journal-title":"J Med Chem."},{"issue":"10","key":"2021122209563806700_CIT0014","doi-asserted-by":"crossref","first-page":"E1819","DOI":"10.1210\/jc.2014-1702","article-title":"A reversible albumin-binding growth hormone derivative is well tolerated and possesses a potential once-weekly treatment profile","volume":"99","author":"Rasmussen","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2021122209563806700_CIT0015","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1210\/jc.2015-1991","article-title":"Reversible albumin-binding GH possesses a potential once-weekly treatment profile in adult growth hormone deficiency","volume":"101","author":"Rasmussen","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"2021122209563806700_CIT0016","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/cen.13409","article-title":"Somapacitan, a once-weekly reversible albumin-binding GH derivative, in children with GH deficiency: a randomized dose-escalation trial","volume":"87","author":"Battelino","year":"2017","journal-title":"Clin Endocrinol (Oxf)."},{"key":"2021122209563806700_CIT0017","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgz310","article-title":"on behalf of the REAL 3 study group. Once-weekly somapacitan versus daily GH in children with GH deficiency: results from a randomized phase 2 trial","author":"S\u00e4vendahl","year":"2020","journal-title":"J Clin Endocrinol Metab."},{"issue":"5","key":"2021122209563806700_CIT0018","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1530\/EJE-17-1073","article-title":"Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial","volume":"178","author":"Johannsson","year":"2018","journal-title":"Eur J Endocrinol."},{"key":"2021122209563806700_CIT0019","volume-title":"ICH Harmonised Tripartite Guideline for Good Clinical Practice","author":"International Conference on Harmonisation","year":"1996"},{"issue":"20","key":"2021122209563806700_CIT0020","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA."},{"issue":"5","key":"2021122209563806700_CIT0021","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1210\/jc.2013-3059","article-title":"Reference intervals for insulin-like growth factor-1 (igf-i) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recommendations","volume":"99","author":"Bidlingmaier","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"issue":"5","key":"2021122209563806700_CIT0022","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1210\/jc.2013-3060","article-title":"Age- and sex-specific reference intervals across life span for insulin-like growth factor binding protein 3 (IGFBP-3) and the IGF-I to IGFBP-3 ratio measured by new automated chemiluminescence assays","volume":"99","author":"Friedrich","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"issue":"9","key":"2021122209563806700_CIT0023","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S2213-8587(19)30084-1","article-title":"Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement","volume":"7","author":"Neeland","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"6","key":"2021122209563806700_CIT0024","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nrendo.2013.64","article-title":"The GH\/IGF-1 axis in obesity: pathophysiology and therapeutic considerations","volume":"9","author":"Berryman","year":"2013","journal-title":"Nat Rev Endocrinol."},{"issue":"9","key":"2021122209563806700_CIT0025","first-page":"2877","article-title":"Two years of growth hormone (GH) treatment increase isometric and isokinetic muscle strength in GH-deficient adults","volume":"82","author":"Johannsson","year":"1997","journal-title":"J Clin Endocrinol Metab."},{"issue":"5","key":"2021122209563806700_CIT0026","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1210\/jc.2003-030840","article-title":"Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a Metaanalysis of Blinded, Randomized, Placebo-Controlled Trials","volume":"89","author":"Maison","year":"2004","journal-title":"J Clin Endocrinol Metab."},{"issue":"5","key":"2021122209563806700_CIT0027","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1210\/er.2003-0035","article-title":"Estrogen regulation of growth hormone action","volume":"25","author":"Leung","year":"2004","journal-title":"Endocr Rev."},{"issue":"1","key":"2021122209563806700_CIT0028","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s40262-018-0662-5","article-title":"Pharmacokinetics and pharmacodynamics of once-weekly somapacitan in children and adults: supporting dosing rationales with a model-based analysis of three phase I trials","volume":"58","author":"Juul","year":"2019","journal-title":"Clin Pharmacokinet."},{"issue":"3","key":"2021122209563806700_CIT0029","first-page":"1222","article-title":"Long-term effects of continuous subcutaneous infusion versus daily subcutaneous injections of growth hormone (GH) on the insulin-like growth factor system, insulin sensitivity, body composition, and bone and lipoprotein metabolism in GH-deficient adults","volume":"86","author":"Laursen","year":"2001","journal-title":"J Clin Endocrinol Metab."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgaa049\/32354971\/dgaa049.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/105\/4\/e1358\/41857591\/jcem_105_4_e1358.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/105\/4\/e1358\/41857591\/jcem_105_4_e1358.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T12:52:52Z","timestamp":1640177572000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/105\/4\/e1358\/5727871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,5]]},"references-count":29,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,2,5]]},"published-print":{"date-parts":[[2020,4,1]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgaa049","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,4]]},"published":{"date-parts":[[2020,2,5]]}}}